Free Trial

IceCure Medical Q2 2023 Earnings Report

IceCure Medical logo
$1.08 -0.04 (-3.57%)
(As of 12:23 PM ET)

IceCure Medical EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.09
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

IceCure Medical Revenue Results

Actual Revenue
$0.94 million
Expected Revenue
$0.80 million
Beat/Miss
Beat by +$140.00 thousand
YoY Revenue Growth
N/A

IceCure Medical Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

TSLA *BANG* incoming (bullet in the chamber rn) (Ad)

I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’s promise, and a secret Elon project set to revolutionize a $23 Trillion market…

Click here to review Tim’s special Holiday offer before it’s too late.

IceCure Medical Earnings Headlines

Icecure Medical: Strong Growth and Regulatory Momentum Support Buy Rating
Mysterious drone activity triggers massive 1,366% surge
If mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%.
IceCure Medical Sees Strong Growth Amid ProSense® Adoption
See More IceCure Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IceCure Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IceCure Medical and other key companies, straight to your email.

About IceCure Medical

IceCure Medical (NASDAQ:ICCM), a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

View IceCure Medical Profile

More Earnings Resources from MarketBeat